EBEmily A. Brennan

Emily A. Brennan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Emily A. Brennan has a total of 108 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Infant Population Simple Search (0-23 months) (PubMed).

    by Lynn Kysh, Zoe Baker, Roxanne Bogucka, Emily A. Brennan, Rachel J. Hinrichs, Christine Willis

    This is a simple, yet sensitive validated search hedge for the infant population (0-23 months) for use in PubMed. Based on the study published in JMLA, this search hedge has 83.5% sensitivity and 89.7% specificity. See the paper for more detail.

  • Open Access

    Infant Population Comprehensive Search (0-23 months) (MEDLINE).

    by Lynn Kysh, Zoe Baker, Roxanne Bogucka, Emily A. Brennan, Rachel J. Hinrichs, Christine Willis

    This is a sensitive, comprehensive, validated search hedge for the infant population (0-23 months) for use in MEDLINE Ovid. Based on the study published in JMLA, this search hedge has 83.6% sensitivity and 88.1% specificity. The All Fields tags can be switched out to text word or title/abstract tags with little change to the sensitivity and specificity. See the paper for more detail.

  • Open Access

    Infant Population Comprehensive Search (0-23 months) (PubMed).

    by Lynn Kysh, Zoe Baker, Roxanne Bogucka, Emily A. Brennan, Rachel J. Hinrichs, Christine Willis

    This is a sensitive, comprehensive, validated search hedge for the infant population (0-23 months) for use in PubMed. Based on the study published in JMLA, this search hedge has 83.8% sensitivity and 88.2% specificity. The All Fields tags can be switched out to text word or title/abstract tags with little change to the sensitivity and specificity. See the paper for more detail.

  • Open Access

    Maxillomandibular Advancement Outcomes in Obstructive Sleep Apnea by Age and Gender

    by Matthew O. Herbst, Lucas C. Licaj, Ethan M. Kallenberger, Shaun A. Nguyen, Courtney Chou, Allen Huang, Emily A. Brennan, Mohamed Abdelwahab

    Objective: Maxillomandibular advancement (MMA) is the most effective surgical treatment for obstructive sleep apnea (OSA) after tracheotomy. However, the influence of patient characteristics such as age and gender on MMA outcomes remains understudied. This meta‐analysis evaluates MMA outcomes stratified by age and gender. Data Sources: A comprehensive literature search of CINAHL, Cochrane Library, PubMed, and Scopus was performed from inception through 2026. Studies reporting age‐ or gender‐specific outcomes of MMA for adults with OSA were included. Review Methods: Extracted data included cephalometric measurements, apnea‐hypopnea index (AHI), Epworth Sleepiness Scale (ESS), SpO2 nadir (LSAT), surgical success, and cure rates. Meta‐analysis was performed. Results: Thirty‐six studies comprising 608 patients were included. MMA significantly improved AHI, ESS, and LSAT ( p < 0.05), with no significant differences in improvement between males and females or across age groups. Mean maxillary/mandibular advancement was 9.7/11.7 mm in males and 9.2/10.6 mm in females. Surgical success and cure rates were comparable between genders (OR success = 1.06 [95% CI 0.54–2.10]; OR cure = 1.17 [95% CI 0.51–2.69]). Increasing age was associated with decreased surgical success and cure, although only the decline in odds of cure reached statistical significance (OR = 0.97 annually, p = 0.029). Conclusion: Maxillomandibular advancement yields significant improvements in OSA outcomes regardless of age or gender. While outcomes are generally consistent across groups, clinicians should counsel older adults on the reduced likelihood of surgical cure. Level of Evidence: N/A.

  • Open Access

    Intervention Outcomes for Meniere's Disease: An Umbrella Review

    by Warren B. Chun, Shaun A. Nguyen, John F. Mills, Kaiwen Chen, Neil P. Monaghan, Emily A. Brennan, Jacqueline P. Nguyen, Ted A. Meyer

    Objective: To assess and summarize the outcomes of major pharmacologic, device‐based, and surgical interventions reported in systematic reviews and meta‐analyses for the treatment of Meniere's disease. Data Sources: CINAHL, Cochrane, PubMed, Scopus. Review Methods: Twenty‐two systematic reviews with meta‐analyses of randomized and nonrandomized studies were identified, assessing interventions including gentamicin, corticosteroids, betahistine, positive pressure therapy, adjunctive acupuncture, endolymphatic sac decompression, and cochlear implantation. The review was reported in accordance with PRISMA 2020 and PRISMA‐S, and methods followed Cochrane Handbook guidance. Four investigators extracted data. When possible, data were pooled using a random‐effects model. Outcomes included vertigo control, tinnitus improvement, and adverse events. Results: Intratympanic gentamicin showed the highest vertigo control rate (89%) but carried a mild hearing loss risk and a 23% subjective hearing reduction rate. Intratympanic steroids offered modest benefit with fewer auditory risks. Positive pressure therapy showed mixed results, while acupuncture demonstrated symptomatic benefit when combined with other therapies. Endolymphatic sac decompression achieved 75%–82% control of vertigo initially but declined over time. Cochlear implants improved speech perception and tinnitus in profound hearing loss. No eligible meta‐analyses evaluated antivirals, ventilation tubes, vestibular nerve section, or labyrinthectomy. Conclusion: Intratympanic gentamicin provides the strongest vertigo control but is backed by low‐quality evidence and risks hearing loss. Conservative treatments like intratympanic steroids and betahistine show modest benefit with mixed evidence. Adjunctive options like acupuncture require cautious interpretation due to low‐quality evidence. Surgical and device‐based options demonstrate variable effectiveness, highlighting the need for individualized, symptom‐driven care and further high‐quality trials.


  • Open Access

    Pulsed radiofrequency for treatment of complex regional pain syndrome: A scoping review

    by Kian Bagheri, Cara Wyant, Emily Brennan, Sarah Wade, Catherine Wagner, Alex Reid, Ameet Nagpal

  • Outcomes of Tinnitus Interventions: An Umbrella Review of Systematic Reviews with Meta-Analysis

    by Kaiwen Chen, Neil P. Monaghan, Shaun A. Nguyen, Warren B. Chun, John F. Mills, Emily Brennan, Ted A. Meyer

    Objectives: Tinnitus is a highly prevalent and challenging neurotologic condition affecting over 740 million individuals worldwide. Despite the growing number of studies, treatment approaches remain fragmented and inconsistent. This umbrella review aims to aggregate results from systematic review to comprehensively synthesize the available evidence. Methods: Following PRISMA guidelines, we systematically searched CINAHL, COCHRANE Library, PubMed, and Scopus through April 2025. Systematic reviews with meta-analyses of primary tinnitus interventions were included. Outcomes focused on validated measures of tinnitus severity, distress, loudness, and quality of life. Study quality was assessed using AMSTAR-2. Results: A total of 44 systematic reviews were included, covering 7 intervention domains. Cognitive behavioral therapy (CBT), hearing aids, tinnitus retraining therapy (TRT), and sound/music therapy consistently improved tinnitus-related outcomes (eg, THI reductions up to −14.50, P < .001). Cochlear implantation yielded the largest effects (eg, THI −29.97) but is reserved for patients with moderate-to-profound sensorineural hearing loss who are not adequately helped by hearing aids. Neuromodulation and acupuncture showed modest or inconsistent benefits with high heterogeneity. Conclusions: This umbrella review provides the current and comprehensive analysis of tinnitus treatments. CBT, hearing aids, TRT, and sound/music therapy show consistent benefit. Cochlear implantation offers the greatest effect in patients with moderate-to-profound hearing loss unresponsive to hearing aids. Other therapies show mixed evidence. These findings offer a much-needed evidence framework to guide treatment decisions and future research.


  • Open Access

    Efficacy of eculizumab discontinuation in atypical hemolytic uremic syndrome: a systematic review and meta-analysis

    by Amy Hockman, Sydney Anuskiewicz, Emily Brennan, Saifur R. Chowdhury, Alexander Coltoff, Jacqueline N. Poston, Charles Greenberg, Benjamin Djulbegovic

    Atypical hemolytic uremic syndrome (aHUS), a life-threatening complement-mediated disorder, is now treatable with terminal complement inhibitors like eculizumab. Although effective, these therapies are costly, and increase susceptibility to infections, notably meningococcal disease, raising concerns about long-term use. The optimal duration of complement inhibition remains unclear, prompting efforts to explore the possibility of treatment discontinuation. We conducted a systematic review and meta-analysis to evaluate the benefits and risks of stopping terminal complement inhibitor therapy in aHUS. We searched PubMed, Scopus, and CINAHL for studies of continuing vs stopping anticomplement treatment in aHUS. Of 3303 identified studies, 13 observational studies (3 case control and 10 cohort) comprising 584 patients were included. Overall, continuing treatment was associated with an ∼76% reduction in the odds of relapse (odds ratio [OR], 0.24; 95% confidence interval [CI], 0.09-0.62; P = .01). Study design influenced results: cohort studies showed a more modest effect (OR, 0.40 [95% CI, 0.15-1.09]), whereas case-control studies reported inflated estimates (OR, 0.04; 95% CI, 0.02-0.08; subgroup interaction P = .03). When the analysis was restricted to cohort studies, the effects became uncertain (statistically nonsignificant with large CIs, indicating the possibility that outcomes with continued treatment could be either superior or inferior to those observed after treatment withdrawal, or that there may be no true difference in relapse rates between the 2 therapies). Although current evidence is insufficient to provide personalized guidance on which patients with aHUS can safely discontinue anticomplement therapy, findings from higher-quality studies, which show no statistical difference between continued and discontinued treatment, suggest that discontinuation may be possible for at least some patients.


  • Open Access

    Developing and validating PubMed infant hedges for PubMed and Ovid MEDLINE: a Medical Library Association pediatrics librarians caucus initiative

    by Lynn Kysh, Zoë Baker, Roxanne Bogucka, Emily Brennan, Rachel Hinrichs, Christine Willis

    Background: To support evidence synthesis and clinical searching, a team of librarians developed and validated infant age (birth to 23 months) search hedges for PubMed (National Library of Medicine) and Medline (OVID). Methods: We developed four sensitive hedges by selecting terms that refer to infants. Three of the hedges had identical MeSH terms and keywords but used different field tags, and the fourth was a simple keyword hedge. We compared our hedges to the built-in MeSH-based infant filter. We used relative recall calculations to validate each hedge’s performance against a gold standard reference set. Results: In PubMed the similarly structured hedges performed in a range of 83.2%-83.8% sensitivity and 88.2%-89.7% specificity. The simple keyword hedge performed with an 83.5% sensitivity and 89.7% specificity. The filter generated a 70.1% sensitivity and 96.2% specificity. Similarly, in Ovid Medline, the set of similar hedges performed in a range of 82.9%-83.6% sensitivity and 88.1%-89.4% specificity. The simple keyword hedge performed with an 82.9% sensitivity and 90.8% specificity. The filter generated a 69.6% sensitivity and 96.2% specificity. Discussion: The variation in field tags did not provide a significant difference in the areas of sensitivity and specificity. The filter performed as expected with higher specificity rather than sensitivity. The simple keyword hedge performed better than anticipated with comparable sensitivity and specificity of the more complex hedges. When searching for infant population articles, the simple keyword search and filter work well for quick, clinical searching. For evidence synthesis, we recommend using one of the more sensitive infant hedges.

  • Disparities in Survival of Head and Neck Cancer in the Hispanic Population: Systematic‐Review and Meta‐analysis

    by Alejandro R. Marrero‐Gonzalez, Douglas P. Nanu, Shaun A. Nguyen, Emily A. Brennan, William Greer Albergotti, Bhisham S. Chera, Jennifer L. Harper, John M. Kaczmar, Alexandra E. Kejner, Jason G. Newman, et al.

    Objective: The Hispanic health paradox (HHP), the observation that Hispanic people in the United States often experience better health outcomes than non‐Hispanic people despite having worse prognostic factors, has not been evaluated for patients with head and neck squamous cell carcinoma (HNSCC), a malignancy with marked racial disparities in outcomes. The objective of this study is to evaluate the HHP within the context of HNSCC.Data Sources: CINAHL, PubMed, and Scopus.Review Methods: Studies that compared survival between Hispanic and non‐Hispanic patients with HNSCC in the United States were included. Meta‐analysis of adjusted hazard ratios (aHRs) with 95% confidence intervals (CIs) was conducted to compare overall survival (OS) and cancer‐specific survival (CSS) between Hispanic white (HW) and non‐Hispanic white (NHW) patients with HNSCC.Results: Of 2106 unique abstracts reviewed, 25 studies were included in the systematic review and 22 in the meta‐analysis. Among the 657,185 patients in the meta‐analysis, 6.9% (95% CI: 5.8%‐8.3%) were of Hispanic ethnicity. HW patients had improved OS relative to NHW patients (aHR = 0.90, 95% CI: 0.86‐0.94) among the 17 studies reporting OS and improved CSS relative to NHW patients (aHR = 0.87, 95% CI: 0.80‐0.94) among the 4 studies reporting this outcome.Conclusion: HW people with HNSCC exhibit improved survival relative to NHW people with HNSCC, supporting the HHP in the context of HNSCC. Research is needed to understand the underlying mechanisms, which could provide insights into improving outcomes for all patients with HNSCC.